Chronic Kidney Disease Stage 5
Conditions
Interventions
control group:sodium citrate
Observation group:Nafamostat
Sponsors
The peoples hospital of xuancheng city
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1.Age over 18 years old; 2.Maintenance hemodialysis patients with dialysis duration>3 months; 3.Meet the diagnostic criteria for end-stage renal disease; 4.Accompanied by active bleeding (cerebral hemorrhage, gastrointestinal bleeding, etc.); 5.Knowing the details of this study and voluntarily participating;
Exclusion criteria
Exclusion criteria: 1.Cannot participate in the entire research process; 2.Individuals allergic to the drugs used in this study; 3.Occurrence of combined infections and other systemic infectious diseases or organic lesions; 4.Suffering from hematological disorders and coexisting malignant tumors; 5.Individuals with severe electrolyte abnormalities and concomitant severe hypocalcemia; 6.Long term anticoagulation therapy with warfarin; 7.Mental disorders cannot cooperate with this study;
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Anticoagulant effect; | — |
Secondary
| Measure | Time frame |
|---|---|
| Blood routine;rate of adverse reaction;Coagulation Function;electrolyte;renal function;Adverse reactions; | — |
Countries
China
Contacts
Public ContactMengjie Sun
The peoples hospital of xuancheng city
Outcome results
None listed